Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens

Journal of Acquired Immune Deficiency Syndromes

Volumn 44, Issue 4, 2007, Pages 371-376

  Jamisse, Lilia ^a,b   Balkus, Jennifer ^c   Hitti, Jane ^b,c   Gloyd, Steve ^b   Manuel, Rolanda ^a   Osman, Nafissa ^d   Djedje, Martinho ^a   Farquhar, Carey ^b  

^a MINISTRY OF HEALTH   (Mozambique)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d MAPUTO CENTRAL HOSPITAL   (Mozambique)

Author keywords

Hepatotoxicity; Highly active antiretroviral therapy; Mother to child HIV 1 transmission; Nevirapine; Pregnancy

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIVER TOXICITY; MAJOR CLINICAL STUDY; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN TOXICITY;

ADULT; ALANINE TRANSAMINASE; ANEMIA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTATE AMINOTRANSFERASES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; INFANT, NEWBORN; LIVER; MOZAMBIQUE; NEVIRAPINE; PERIPHERAL NERVOUS SYSTEM DISEASES; PREGNANCY; PROSPECTIVE STUDIES; SKIN; TREATMENT OUTCOME;

EID: 34147115624     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318032bbee     Document Type: Article

References (15)

1. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS. 2001;15:761-770.
2. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494.
3. Wade NA, Zielinski MA, Butsashvili M, et al. Decline in perinatal transmission in New York State (1997-2000). J Acquir Immune Defic Syndr. 2004;36:1035-1082.
4. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination therapy for prevention of maternal-infant transmission of HIV-1. JAMA. 2001;285:2083-2093.
5. World Health Organization. Treating 3 Million by 2005: Making It Happen: the WHO Strategy: the WHO and UNAIDS Global Initiative to Provide Antiretroviral Therapy to 3 Million People With HIV/AIDS in Developing Countries by the End of 2005. World Health Organization; 2003.
6. World Health Organization. Antiretroviral Drugs and the Prevention of Mother-to-Child Transmission of HIV Infection in Resource-Limited Settings: Recommendations for a Public Health Approach (2005 Revision). Geneva, Switzerland: WHO; 2005. Available at: http:// www.who.int/3by5/ PMTCTreport_June2005.pdf.
7. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Guidelines on Care, Treatment and Support for Women Living With HIV/AIDS and Their Children in Resource-Constrained Settings. World Health Organization; 2004.
8. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine and efavirenz-based first-line HAART. AIDS. 2005;19:463-471.
9. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423-1430.
10. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy. J Acquir Immune Defic Syndr. 2004;36:772-776.
11. Timmermans S, Tempelman C, Godfried MH, et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS. 2005;19:795-799.
12. República de Moçambique. Programa Nacional de Controle DTS/SIDA. Guia para o tratamento das infecções oportunistas no adulto infectado por HIV e Profilaxia das infecções oportunistas. Maputo, Mozambique: Ministry of Health; 2004.
13. Joao EC, Calvet GA, Menezes JA, et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol. 2006;194:199-202.
14. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191:825-829.
15. Shepard KV. Clarification of risk factors for severe, life-threatening and fatal hepatic toxicity with VIRAMUNE (nevirapine). Available at: http://www.bidocs.com/renetnt:/Notifications/Dear+HCP+ltr+Feb+ 2004.pdf.